Mineralocorticoid Receptor Blockade in Renal Protection

The mineralocorticoid receptor (MR) mediates the effects of aldosterone in the kidney, modulating electrolyte balance, blood pressure and tissue remodelling. Dysregulated MR activation contributes to renal inflammation, oxidative stress and fibrosis, accelerating progression from acute injury to chronic kidney disease. MR antagonists such as spironolactone and eplerenone can attenuate these deleterious processes by blocking receptor signalling in vascular smooth muscle, tubular epithelial cells and interstitial fibroblasts. Experimental models have demonstrated that MR blockade reduces tubular damage, glomerulosclerosis and interstitial fibrosis in contexts of calcineurin inhibition, ischaemia–reperfusion injury and metabolic stress. Clinically, MR antagonists have shown promise in preserving graft function after transplantation and in mitigating nephrotoxic effects of immunosuppressive drugs. This approach holds significant potential for broad renoprotection across diverse aetiologies, offering a strategy to delay or prevent the onset of irreversible renal decline.

Research from Nature Portfolio

Seminal work has identified urinary serine protease inhibitor SerpinA3 as an early biomarker of the transition from acute kidney injury (AKI) to chronic kidney disease (CKD). Progressive elevation of urinary SerpinA3 correlates with tubular epithelial cell injury and interstitial fibrosis, enabling non-invasive detection of early fibrotic changes. Relocation of SerpinA3 within tubular cells further mirrors the underlying pathology, offering a potential tool to monitor MR antagonist efficacy in preventing the AKI–CKD progression.

Mineralocorticoid Receptor Blockade in Renal Protection publication trend

The graph below shows the total number of articles in mineralocorticoid receptor blockade in renal protection across all publications each year (not limited to Nature Index journals).

Technical terms

Mineralocorticoid receptor (MR): Intracellular receptor activated by aldosterone, regulating renal sodium reabsorption and tissue remodelling.

Ischaemia–reperfusion injury: Tissue damage caused by restoration of blood flow after a period of oxygen deprivation.

Interstitial fibrosis: Excessive deposition of extracellular matrix in the renal interstitium leading to scarring and functional decline.

Glomerular filtration rate (GFR): Measure of renal function indicating the volume of fluid filtered by the glomeruli per unit time.

Biomarker: Measurable substance whose presence or level indicates a biological state, such as disease onset or progression.

References

1. The Mineralocorticoid Receptor on Smooth Muscle Cells Promotes Tacrolimus-Induced Renal Injury in Mice. Pharmaceutics (2023).
2. SerpinA3 in the Early Recognition of Acute Kidney Injury to Chronic Kidney Disease (CKD) transition in the rat and its Potentiality in the Recognition of Patients with CKD. Scientific Reports (2019).
3. Safety of Eplerenone for Kidney-Transplant Recipients with Impaired Renal Function and Receiving Cyclosporine A. PLOS ONE (2016).
4. The mineralocorticoid receptor antagonist eplerenone reduces renal interstitial fibrosis after long-term cyclosporine treatment in rat: antagonizing cyclosporine nephrotoxicity. BMC Nephrology (2013).
5. The effect of spironolactone on calcineurin inhibitor induced nephrotoxicity: a multicenter randomized, double-blind, clinical trial (the SPIREN trial). BMC Nephrology (2018).
6. Oil-In-Water Microemulsion Encapsulation of Antagonist Drugs Prevents Renal Ischemia-Reperfusion Injury in Rats. Applied Sciences (2021).